journal article·2022-12-31Open access

Treatment-related adverse events of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors in clinical trials: a meta-analysis

Ze Mi, Yunshu Zhang, Zhichao Feng, Jiahao Liu, Jianmin Wu, Hongpei Tan, Xiaoqian Ma, Zhenguo Liu, Pengfei Rong

Abstract

Aim PD-1/PD-L1 inhibitors in combination with CTLA-4 inhibitors are being tested in a number of ongoing clinical trials. As a result, it is critical to fully comprehend the toxicity characteristics of adverse events in combination therapy. This study aims to extensively compare the incidences and ORs of treatment-related adverse events between two combination strategies.Methods The eligible articles were searched from PubMed, EMBASE and Cochrane databases for studies published between 1 January 2010 and 1 May 2021, investigating PD-1/PD-L1 inhibitors plus CTLA-4 inhibitor-based combined clinical therapies. The mean incidences and pooled ORs of all-grade and grade 3 or higher adverse events were calculated by random-effects model using Stata 12.1. Heterogeneity between studies was assessed with I2 statistics and Chi square-based Q statistic. The overall risk of bias was assessed by Review Manager 5.3.Results A total of 26 eligible studies of 3607 patients were selected; 2852 patients developed at least one all-grade adverse event. PD-L1 inhibitors plus CTLA-4 inhibitors regimen (incidence 0.67, 95% CI: 0.57–0.77) had marked advantage over PD-1 inhibitors plus CTLA-4 inhibitors regimen (incidence 0.89, 95% CI: 0.86–0.93).Conclusion PD-L1 inhibitors plus CTLA-4 inhibitors shows better safety in treatment-related adverse events than PD-1 inhibitors plus CTLA-4 inhibitors.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Cancer Immunotherapy and Biomarkers · Drug-Induced Adverse Reactions · Diabetes and associated disorders

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Radiology, The Third Xiangya Hospital, Central South University, Changsha, China

Xiangya School of Medicine, Central South University, Changsha, China

Department of Infectious Disease, The Third Xiangya Hospital, Central South University, Changsha, China

Key Laboratory of Biological Nanotechnology of National Health Commission, Central South University, Changsha, China

Funding

National Natural Science Foundation of China · Science and Technology Project of Hunan Province · Furong Scholars Programme of Hunan Province · Wisdom Accumulation and Talent Cultivation Project of the Third Xiangya Hospital of Central South University

References (43)

Show source-provided references
1. 10.1126/science.aar406010.1126/science.aar4060 ↗
2. 10.1056/NEJMoa150764310.1056/NEJMoa1507643 ↗
3. 10.1056/NEJMoa171212610.1056/NEJMoa1712126 ↗
4. 10.1200/JCO.2017.76.990110.1200/JCO.2017.76.9901 ↗
5. 10.1056/NEJMoa170968410.1056/NEJMoa1709684 ↗
6. 10.1186/s13046-019-1259-z10.1186/s13046-019-1259-z ↗
7. 10.1038/s41591-018-0198-010.1038/s41591-018-0198-0 ↗
8. 10.1056/NEJMoa191023110.1056/NEJMoa1910231 ↗
9. 10.1016/S1470-2045(18)30006-810.1016/S1470-2045(18)30006-8 ↗
10. 10.1093/annonc/mdx64210.1093/annonc/mdx642 ↗
11. 10.1016/j.lungcan.2018.12.01510.1016/j.lungcan.2018.12.015 ↗
12. 10.1016/j.annonc.2020.11.02010.1016/j.annonc.2020.11.020 ↗
13. 10.1016/S1470-2045(15)00544-610.1016/S1470-2045(15)00544-6 ↗
14. 10.1016/j.ejca.2020.10.02710.1016/j.ejca.2020.10.027 ↗
15. 10.1016/S2213-2600(18)30151-610.1016/S2213-2600(18)30151-6 ↗
16. 10.1093/annonc/mdz28610.1093/annonc/mdz286 ↗
17. 10.3389/fphar.2020.0004010.3389/fphar.2020.00040 ↗
18. 10.1186/s12885-019-5785-z10.1186/s12885-019-5785-z ↗
19. 10.1016/S1470-2045(21)00333-810.1016/S1470-2045(21)00333-8 ↗
20. 10.1126/scitranslmed.300800210.1126/scitranslmed.3008002 ↗
21. 10.3389/fonc.2020.0009110.3389/fonc.2020.00091 ↗
22. 10.1001/jamaoncol.2019.039310.1001/jamaoncol.2019.0393 ↗
23. 10.1038/s41375-020-0939-110.1038/s41375-020-0939-1 ↗
24. 10.1016/S1470-2045(16)30366-710.1016/S1470-2045(16)30366-7 ↗
25. 10.1056/NEJMoa150403010.1056/NEJMoa1504030 ↗
26. 10.1158/1078-0432.CCR-19-335610.1158/1078-0432.CCR-19-3356 ↗
27. 10.1016/S1470-2045(18)30765-410.1016/S1470-2045(18)30765-4 ↗
28. 10.1001/jamaoncol.2020.295510.1001/jamaoncol.2020.2955 ↗
29. 10.1056/NEJMoa130236910.1056/NEJMoa1302369 ↗
30. 10.1016/S1470-2045(16)30098-510.1016/S1470-2045(16)30098-5 ↗
31. 10.1016/S1470-2045(19)30413-910.1016/S1470-2045(19)30413-9 ↗
32. 10.1056/NEJMoa180545310.1056/NEJMoa1805453 ↗
33. 10.1200/JCO.2017.76.621210.1200/JCO.2017.76.6212 ↗
34. 10.1016/S0140-6736(20)30417-710.1016/S0140-6736(20)30417-7 ↗
35. 10.1001/jamaoncol.2020.091010.1001/jamaoncol.2020.0910 ↗
36. 10.1001/jamaoncol.2018.462810.1001/jamaoncol.2018.4628 ↗
37. 10.1016/S1470-2045(20)30541-610.1016/S1470-2045(20)30541-6 ↗
38. 10.1038/s41591-020-1086-y10.1038/s41591-020-1086-y ↗
39. 10.1016/j.annonc.2020.04.00110.1016/j.annonc.2020.04.001 ↗
40. 10.3389/fonc.2020.0025810.3389/fonc.2020.00258 ↗
41. 10.1002/ijc.3125210.1002/ijc.31252 ↗
42. 10.1016/j.cell.2020.06.00110.1016/j.cell.2020.06.001 ↗
43. 10.1002/sim.176110.1002/sim.1761 ↗